Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOSEPH YE

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1700881422
CMS profile
259019
Location
OLYMPIA, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$14,128.57

178 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Ipsen Biopharmaceuticals, Inc $3,196.41 7
Astellas Pharma Global Development $2,172.00 1
Karyopharm Therapeutics Inc. $1,692.37 2
AstraZeneca Pharmaceuticals LP $1,444.17 13
PFIZER INC. $1,282.24 15
GENZYME CORPORATION $994.76 6
ABBVIE INC. $454.72 17
Astellas Pharma US Inc $276.10 7
Merck Sharp & Dohme LLC $191.69 9
Novartis Pharmaceuticals Corporation $181.67 7
Celgene Corporation $178.30 7
E.R. Squibb & Sons, L.L.C. $168.84 7
Incyte Corporation $167.48 8
GlaxoSmithKline, LLC. $151.39 7
Janssen Biotech, Inc. $104.39 4
TAIHO ONCOLOGY, INC. $104.16 5
BeiGene USA, Inc. $98.65 4
Genentech USA, Inc. $97.37 3
Genmab U.S., Inc. $96.12 3
Dendreon Pharmaceuticals LLC $94.90 3
Tempus AI, Inc $91.32 3
Bayer Healthcare Pharmaceuticals Inc. $75.11 4
Lilly USA, LLC $67.87 3
Exelixis Inc. $59.49 2
ARRAY BIOPHARMA INC $55.21 3
Stemline Therapeutics Inc. $55.02 2
Mirati Therapeutics, Inc. $52.86 2
Regeneron Healthcare Solutions, Inc. $50.71 2
Coherus Biosciences Inc. $49.60 2
Deciphera Pharmaceuticals Inc. $47.52 1
Daiichi Sankyo Inc. $43.00 2
ADC Therapeutics America, Inc. $37.58 2
Apellis Pharmaceuticals, Inc. $35.90 2
Takeda Pharmaceuticals U.S.A., Inc. $26.05 1
TerSera Therapeutics LLC $24.52 1
ACCORD HEALTHCARE, INC. $22.57 1
Janssen Pharmaceuticals, Inc $22.00 1
Sumitomo Pharma America, Inc. $21.08 1
Agios Pharmaceuticals, Inc. $20.64 1
Gilead Sciences, Inc. $20.62 1
Pharmacosmos Therapeutics Inc. $19.79 1
PUMA BIOTECHNOLOGY, INC. $17.93 1
Blueprint Medicines Corporation $17.79 1
Azurity Pharmaceuticals, Inc. $16.40 1
JAZZ PHARMACEUTICALS INC. $16.14 1
SERVIER PHARMACEUTICALS LLC $14.12 1

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOSEPH YE

NPI 1700881422 · CMS profile ID 259019

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

OLYMPIA, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700881422?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOSEPH YE, NPI 1700881422, CMS profile ID 259019. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700881422?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOSEPH YE, NPI 1700881422, CMS profile ID 259019. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700881422?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOSEPH YE, NPI 1700881422, CMS profile ID 259019, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 178 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1700881422?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

178 matching records · $14,128.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 178 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 178.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $27.3209/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104675661 CMS
AstraZeneca Pharmaceuticals LP $20.4409/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104462820 CMS
GlaxoSmithKline, LLC. $11.9809/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116415581 CMS
Tempus AI, Inc $39.6909/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150177479 CMS
Astellas Pharma US Inc $99.9909/17/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139408387 CMS
Janssen Biotech, Inc. $20.5609/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078825885 CMS
ABBVIE INC. $16.3309/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373812 CMS
ABBVIE INC. $18.7009/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373810 CMS
ABBVIE INC. $59.9509/10/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373808 CMS
SERVIER PHARMACEUTICALS LLC $14.1209/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147260898 CMS
GENZYME CORPORATION $40.2609/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139729304 CMS
Novartis Pharmaceuticals Corporation $28.8409/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087371056 CMS
ADC Therapeutics America, Inc. $14.8608/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121191041 CMS
Astellas Pharma US Inc $25.9208/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139355899 CMS
PFIZER INC. $1,000.0008/26/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131940981 CMS
Astellas Pharma US Inc $14.1508/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139367013 CMS
Blueprint Medicines Corporation $17.7908/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147441598 CMS
Ipsen Biopharmaceuticals, Inc $14.0208/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091951283 CMS
Celgene Corporation $41.1408/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101174408 CMS
TAIHO ONCOLOGY, INC. $14.0908/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137945284 CMS
ARRAY BIOPHARMA INC $27.4308/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131369268 CMS
ARRAY BIOPHARMA INC $1.8408/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131369273 CMS
PFIZER INC. $25.3608/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131344465 CMS
PFIZER INC. $32.7708/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131342584 CMS
Pharmacosmos Therapeutics Inc. $19.7908/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154827185 CMS
AstraZeneca Pharmaceuticals LP $17.1608/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104683667 CMS
Novartis Pharmaceuticals Corporation $25.7308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087371058 CMS
PFIZER INC. $9.9408/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131785766 CMS
PFIZER INC. $1.8008/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131900447 CMS
GlaxoSmithKline, LLC. $26.5208/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116595949 CMS
PFIZER INC. $21.6508/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131900445 CMS
Novartis Pharmaceuticals Corporation $27.5007/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087371054 CMS
ABBVIE INC. $24.8507/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373806 CMS
Merck Sharp & Dohme LLC $30.3007/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141640849 CMS
Bayer Healthcare Pharmaceuticals Inc. $19.0507/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086225460 CMS
Regeneron Healthcare Solutions, Inc. $27.6307/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114258832 CMS
PFIZER INC. $120.3707/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131810738 CMS
Agios Pharmaceuticals, Inc. $20.6407/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149644657 CMS
Merck Sharp & Dohme LLC $18.5207/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141851200 CMS
Dendreon Pharmaceuticals LLC $32.0407/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1149325988 CMS
GENZYME CORPORATION $39.4807/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139729292 CMS
PFIZER INC. $0.9707/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131344460 CMS
PFIZER INC. $4.1007/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131345618 CMS
Apellis Pharmaceuticals, Inc. $18.7507/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154024003 CMS
AstraZeneca Pharmaceuticals LP $86.1107/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104742673 CMS
Genmab U.S., Inc. $31.9407/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1126828120 CMS
TAIHO ONCOLOGY, INC. $26.1007/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137938652 CMS
Bayer Healthcare Pharmaceuticals Inc. $21.9907/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086183728 CMS
ABBVIE INC. $23.5707/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1106373804 CMS
Merck Sharp & Dohme LLC $18.4207/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141640851 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $21,604.02 220
PY2020 $8,921.51 164
PY2021 $8,788.71 243
PY2022 $27,377.48 251
PY2023 $20,385.00 206
PY2024 $14,128.57 178
PY2025 $13,635.78 225

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,734,361.33 126
PY2024 Principal investigator $1,347,808.17 60
PY2023 Principal investigator $422,187.02 31
PY2022 Recipient $2,830.85 2
PY2022 Principal investigator $148,847.56 23
PY2021 Recipient $23,810.46 5
PY2021 Principal investigator $119,144.67 17
PY2020 Principal investigator $35,689.74 15
PY2019 Principal investigator $49,464.45 28

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

126 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $82.00 12/31/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK LLC
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE-FL-2) No dispute reported 06/30/2026 1202534821
Principal investigator 1 PFIZER INC. $232.40 12/26/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716793
Principal investigator 1 Janssen Research & Development, LLC $8,803.00 12/22/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175415054
Principal investigator 1 ABBVIE INC. $35,850.00 12/18/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202531148
Principal investigator 1 ABBVIE INC. $16,782.08 12/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202526964
Principal investigator 1 ABBVIE INC. $10,236.16 12/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202526968
Principal investigator 1 PFIZER INC. $116.20 12/01/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717141
Principal investigator 1 PFIZER INC. $47,181.76 12/01/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719301
Principal investigator 1 PFIZER INC. $10,175.00 12/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228806888
Principal investigator 1 PFIZER INC. $100,815.00 12/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228807515
Principal investigator 1 PFIZER INC. $29,849.28 12/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED PHASE 3 OPENLABEL STUDY TO EVALUATE SGNB6A COMPARED WITH DOCETAXEL IN ADULT SUBJECTS WITH PREVIOUSLY TREATED NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228807521
Principal investigator 1 Incyte Corporation $118.76 11/25/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240502047
Principal investigator 1 PFIZER INC. $23,590.88 11/25/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719307
Principal investigator 1 PFIZER INC. $232.40 11/24/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716795
Principal investigator 1 ABBVIE INC. $8,750.00 11/20/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202524794
Principal investigator 1 PFIZER INC. $557.76 11/17/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717571
Principal investigator 1 PFIZER INC. $47,181.76 11/17/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719175
Principal investigator 1 PFIZER INC. $23,590.88 11/12/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719105
Principal investigator 1 PFIZER INC. $232.40 11/11/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716799
Principal investigator 1 Incyte Corporation $102,857.83 11/10/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240502043
Principal investigator 1 PFIZER INC. $116.20 11/10/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716619
Principal investigator 1 PFIZER INC. $58,977.20 11/10/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719103
Principal investigator 1 ABBVIE INC. $13,534.72 11/05/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202521605
Principal investigator 1 ABBVIE INC. $12,614.40 11/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202520273
Principal investigator 1 ABBVIE INC. $6,359.04 11/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202520275
Principal investigator 1 PFIZER INC. $58,977.20 11/04/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719298
Principal investigator 1 Incyte Corporation $642.00 10/30/2025 Non-covered Recipient Entity
CANCER CENTER FOR BLOOD DISORDERS A DIVISION OF AMERICAN ONCOLOGY PARTNERS P.A
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma No dispute reported 06/30/2026 1240512049
Principal investigator 1 Novocure Inc. $2,500.00 10/30/2025 Non-covered Recipient Entity
American Onocology Partners, PA
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856687
Principal investigator 1 PFIZER INC. $23,590.88 10/28/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719303
Principal investigator 1 PFIZER INC. $813.40 10/27/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717577
Principal investigator 1 PFIZER INC. $23,590.88 10/22/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719099
Principal investigator 1 PFIZER INC. $107,237.00 10/14/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228807510
Principal investigator 1 ABBVIE INC. $13,012.48 10/09/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202514979
Principal investigator 1 ABBVIE INC. $2,119.68 10/09/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202514981
Principal investigator 1 ABBVIE INC. $25,153.28 10/09/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202514983
Principal investigator 1 Janssen Research & Development, LLC $35,500.00 10/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175415076
Principal investigator 1 PFIZER INC. $232.40 09/29/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717313
Principal investigator 1 PFIZER INC. $188,727.04 09/23/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719305
Principal investigator 1 GlaxoSmithKline, LLC. $7,800.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117289
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117297
Principal investigator 1 GlaxoSmithKline, LLC. $1,300.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117307
Principal investigator 1 GlaxoSmithKline, LLC. $1,170.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192117313
Principal investigator 1 GlaxoSmithKline, LLC. $650.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122055
Principal investigator 1 GlaxoSmithKline, LLC. $1,170.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122059
Principal investigator 1 GlaxoSmithKline, LLC. $1,950.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122065
Principal investigator 1 GlaxoSmithKline, LLC. $3,250.00 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122070
Principal investigator 1 GlaxoSmithKline, LLC. $3,294.20 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122075
Principal investigator 1 GlaxoSmithKline, LLC. $9,812.40 09/17/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122082
Principal investigator 1 PFIZER INC. $348.60 09/15/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716967
Principal investigator 1 PFIZER INC. $58,977.20 09/09/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719173
Principal investigator 1 PFIZER INC. $232.40 09/08/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717575
Principal investigator 1 ABBVIE INC. $26,773.76 09/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202509694
Principal investigator 1 ABBVIE INC. $4,239.36 09/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202508286
Principal investigator 1 PFIZER INC. $23,590.88 09/02/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719095
Principal investigator 1 Janssen Research & Development, LLC $3,672.00 09/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175415018
Principal investigator 1 PFIZER INC. $232.40 08/29/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717145
Principal investigator 1 PFIZER INC. $232.40 08/29/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717311
Principal investigator 1 AstraZeneca Pharmaceuticals LP $66,291.50 08/27/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK, LLC
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 No dispute reported 06/30/2026 1185555063
Principal investigator 1 ABBVIE INC. $23,232.29 08/25/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202505671
Principal investigator 1 PFIZER INC. $47,181.76 08/25/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719177
Principal investigator 1 PFIZER INC. $23,590.88 08/19/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228718971
Principal investigator 1 PFIZER INC. $92.96 08/18/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717573
Principal investigator 1 PFIZER INC. $232.40 08/13/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716615
Principal investigator 1 PFIZER INC. $205.75 08/11/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716617
Principal investigator 1 PFIZER INC. $23,590.88 08/11/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228718969
Principal investigator 1 PFIZER INC. $205.75 08/11/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719169
Principal investigator 1 PFIZER INC. $23,590.88 08/07/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228718974
Principal investigator 1 ABBVIE INC. $7,087.36 08/06/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202502588
Principal investigator 1 PFIZER INC. $92.96 08/06/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717307
Principal investigator 1 ABBVIE INC. $8,478.72 08/05/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202501474
Principal investigator 1 PFIZER INC. $185.92 08/04/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716797
Principal investigator 1 PFIZER INC. $27,455.00 08/04/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228835218
Principal investigator 1 PFIZER INC. $232.40 07/28/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717309
Principal investigator 1 PFIZER INC. $94,363.52 07/28/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719101
Principal investigator 1 Janssen Research & Development, LLC $11,061.00 07/22/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175415031
Principal investigator 1 PFIZER INC. $23.24 07/21/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228717143
Principal investigator 1 PFIZER INC. $11,795.44 07/21/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719171
Principal investigator 1 PFIZER INC. $139.44 07/17/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716621
Principal investigator 1 PFIZER INC. $23,590.88 07/17/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719226
Principal investigator 1 PFIZER INC. $29,488.60 07/08/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719229
Principal investigator 1 PFIZER INC. $116.20 07/07/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228716969
Principal investigator 1 PFIZER INC. $29,488.60 07/07/2025 Non-covered Recipient Entity
Vista Oncology Inc PS
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228719231
Principal investigator 1 PFIZER INC. $33,570.00 07/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228845910
Principal investigator 1 ABBVIE INC. $17,530.88 07/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202494803
Principal investigator 1 ABBVIE INC. $16,490.24 07/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations No dispute reported 06/30/2026 1202496459
Principal investigator 1 ABBVIE INC. $13,338.88 07/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202496471
Principal investigator 1 ABBVIE INC. $28,565.76 07/02/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202496481
Principal investigator 1 Janssen Research & Development, LLC $3,249.00 07/01/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175414965
Principal investigator 1 PFIZER INC. $116.20 06/27/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228834997
Principal investigator 1 PFIZER INC. $116.20 06/26/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228823131
Principal investigator 1 GlaxoSmithKline, LLC. $4,151.86 06/10/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122041
Principal investigator 1 ABBVIE INC. $35,157.76 06/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202487799
Principal investigator 1 ABBVIE INC. $21,153.10 06/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202487801
Principal investigator 1 ABBVIE INC. $5,835.52 06/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202487803
Principal investigator 1 GlaxoSmithKline, LLC. $16,607.45 05/16/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE No dispute reported 06/30/2026 1192122048
Principal investigator 1 Novocure Inc. $2,591.82 05/15/2025 Non-covered Recipient Entity
American Onocology Partners, PA
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856791
Principal investigator 1 AstraZeneca UK Limited $54,007.40 05/08/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY NETWORK, LLC
Prospective, Open-Label, Single-Arm, Phase II Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL (ACRUE) No dispute reported 06/30/2026 1185555061
Principal investigator 1 ABBVIE INC. $15,119.36 05/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202483175
Principal investigator 1 ABBVIE INC. $27,480.08 05/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202483177
Principal investigator 1 ABBVIE INC. $14,639.36 05/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202483249
Principal investigator 1 PFIZER INC. $70,772.64 04/29/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228834275
Principal investigator 1 PFIZER INC. $70,772.64 04/28/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228823073
Principal investigator 1 Incyte Corporation $8,671.26 04/15/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS OF MARYLAND, PA
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240502039
Principal investigator 1 PFIZER INC. $43,187.00 04/14/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228853311
Principal investigator 1 PFIZER INC. $47,181.76 04/10/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228834269
Principal investigator 1 PFIZER INC. $47,181.76 04/09/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228823078
Principal investigator 1 ABBVIE INC. $16,195.78 04/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202470388
Principal investigator 1 ABBVIE INC. $19,508.48 04/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202470393
Principal investigator 1 ABBVIE INC. $4,513.28 04/03/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202470398
Principal investigator 1 PFIZER INC. $70,772.64 03/28/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228835004
Principal investigator 1 PFIZER INC. $70,772.64 03/18/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228823139
Principal investigator 1 ABBVIE INC. $26,855.04 03/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202459122
Principal investigator 1 ABBVIE INC. $17,081.60 03/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202459126
Principal investigator 1 ABBVIE INC. $3,084.80 03/07/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M23-721 - Study to Evaluate Adverse Events Optimal Dose and Change in Disease Activity With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202462012
Principal investigator 1 Novocure Inc. $1,270.08 03/06/2025 Non-covered Recipient Entity
American Onocology Partners, PA
EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma No dispute reported 06/30/2026 1250856789
Principal investigator 1 Astellas Pharma Global Development $2,589.00 02/20/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234181756
Principal investigator 1 PFIZER INC. $52,857.00 02/18/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228853230
Principal investigator 1 Astellas Pharma Global Development $13,490.00 02/13/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234181750
Principal investigator 1 Astellas Pharma Global Development $9,672.00 02/13/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234181752
Principal investigator 1 Astellas Pharma Global Development $2,000.00 02/13/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma No dispute reported 06/30/2026 1234181754
Principal investigator 1 ABBVIE INC. $13,578.24 02/06/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCOREFL-2) No dispute reported 06/30/2026 1202446731
Principal investigator 1 ABBVIE INC. $5,506.56 02/06/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma No dispute reported 06/30/2026 1202446735
Principal investigator 1 ABBVIE INC. $1,128.32 02/06/2025 Non-covered Recipient Entity
AMERICAN ONCOLOGY PARTNERS PA
M24-287 - A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) No dispute reported 06/30/2026 1202446738
Principal investigator 1 PFIZER INC. $70,772.64 01/30/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228834992
Principal investigator 1 PFIZER INC. $70,772.64 01/28/2025 Non-covered Recipient Entity
American Oncology Network Vista Oncology DivisionEast office
A PHASE 1 STUDY OF SGNB6A IN ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228823125
Principal investigator 1 Incyte Corporation $21,059.38 01/14/2025 Non-covered Recipient Entity
VISTA ONCOLOGY INC PS
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240615676